Once-a-month HIV PrEP could be the future and replace daily

Once-a-month HIV PrEP could be the future and replace daily pills


Truvada is one of the ARV drugs that are currently used as a daily pre-exposure prophylaxis, or PrEP.
Image: 123RF/Alexander Raths
Women who are at risk of HIV infection and are using HIV pre-exposure prophylaxis (PrEP) on a daily basis might in the near future have to use only one pill a month, if a trial conducted in SA and other parts of the world is successful.
This week the efficacy study, which is led by the University of Washington, received a $122m grant from the Bill & Melinda Gates Foundation to test the effectiveness of a once-a-month oral pill to prevent HIV.

Related Keywords

Kenya , Malawi , Zambia , Uganda , Zimbabwe , Connie Celum , University Of Washington , Melinda Gates Foundation , Sub Saharan Africa , Study , Impower 22 , Hiv Prep , South Africa , Bill Amp Melinda Gates Foundation , கேந்ய , மலாவி , சாம்பியா , உகந்த , ஸிஂபாப்வே , பல்கலைக்கழகம் ஆஃப் வாஷிங்டன் , மெலிண்டா வாயில்கள் அடித்தளம் , படிப்பு , ர சி து ஆம்ப் மெலிண்டா வாயில்கள் அடித்தளம் ,

© 2025 Vimarsana